Objective: Pharmacological treatment of anxiety disorders is an active research field and Selective Serotonin Reuptake Inhibitors (SSRIs) are considered to be the first line of drugs in this treatment. In cases resistant to SSRI, in addition to serotonin-noradrenaline reuptake inhibitors (SNRIs), antiepileptic drugs that have anxiolytic activity by increasing the efficiency of gamma-aminobutyric acid (GABA) such as valproate can be used.
Methods: Observational case report.
Results: The author describes the use of valproic acid in the treatment of a patient who had resistant anxiety symptoms despite the treatment with SSRIs and SNRIs in appropriate doses for appropriate time.
Conclusions: The favorable response obtained with the use of valproate outside of its classical indications in our patient who was resistant to antidepressants indicates that valproate should be considered in anxiety disorders.